[Inhibition of platelet aggregation under estrogen-treatment in patients with carcinoma of the prostate (author's transl)].
In patients with carcinoma of the prostate treated with estrogens platelet aggregation is increased. Patients with increased platelet aggregation have a high incidence of cardio-vascular and thrombo-embolic diseases. Platelet aggregation was measured by the platelet-aggregation test (PAT). Platelet aggregation was inhibited by administration of acetyl-salicylic acid (ASS) 2 times 500 mg daily. An aggregation inhibiting effect was found in all 38 patients. To reduce the cardio-vascular complications of estrogens in treating carcinoma of the prostate acetyl-salicylic acid as an adjunct therapy is recommended. A long-term study has been started.
D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001778:Blood Coagulation Disorders / Q000517:prevention & control; D001792:Blood Platelets / Q000187:drug effects*; D004054:Diethylstilbestrol / Q000008:administration & dosage; D004967:Estrogens / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D010973:Platelet Adhesiveness; D010974:Platelet Aggregation; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013927:Thrombosis / Q000517:prevention & control
D004967:Estrogens; D004054:Diethylstilbestrol; D001241:Aspirin
Thrombocyten-Aggregationshemmung bei Oestrogen-behandelten Prostata-Carcinom-Patienten